284 related articles for article (PubMed ID: 30209184)
41. Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Geraets DT; Cuschieri K; de Koning MN; van Doorn LJ; Snijders PJ; Meijer CJ; Quint WG; Arbyn M
J Clin Microbiol; 2014 Nov; 52(11):3996-4002. PubMed ID: 25210073
[TBL] [Abstract][Full Text] [Related]
42. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
43. Machine Learning Interpretation of Extended Human Papillomavirus Genotyping by Onclarity in an Asian Cervical Cancer Screening Population.
Wong OGW; Ng IFY; Tsun OKL; Pang HH; Ip PPC; Cheung ANY
J Clin Microbiol; 2019 Dec; 57(12):. PubMed ID: 31511337
[TBL] [Abstract][Full Text] [Related]
44. Comparison of hybrid capture 2 High-Risk HPV results in the low positive range with cobas® HPV Test results from the ATHENA study.
Rao A; Sandri MT; Sideri M; Young S; Sharma A; Behrens C
J Clin Virol; 2013 Sep; 58(1):161-7. PubMed ID: 23895930
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of the clinical performance of OncoPredict HPV® SCR assay within the VALGENT-2 framework.
Dhillon SK; Cocuzza CE; Chung PYJ; Martinelli M; Giubbi C; Njoku RC; Bhatia R; Cuschieri K; Arbyn M
J Med Virol; 2023 Jan; 95(1):e28417. PubMed ID: 36541733
[TBL] [Abstract][Full Text] [Related]
46. HPV genotype-specific concordance between EuroArray HPV, Anyplex II HPV28 and Linear Array HPV Genotyping test in Australian cervical samples.
Cornall AM; Poljak M; Garland SM; Phillips S; Machalek DA; Tan JH; Quinn MA; Tabrizi SN
Papillomavirus Res; 2017 Dec; 4():79-84. PubMed ID: 29179874
[TBL] [Abstract][Full Text] [Related]
47. Comparison of clinical and analytical performance of the Abbott Realtime High Risk HPV test to the performance of hybrid capture 2 in population-based cervical cancer screening.
Poljak M; Ostrbenk A; Seme K; Ucakar V; Hillemanns P; Bokal EV; Jancar N; Klavs I
J Clin Microbiol; 2011 May; 49(5):1721-9. PubMed ID: 21430098
[TBL] [Abstract][Full Text] [Related]
48. Validation of a Human Papillomavirus (HPV) DNA Cervical Screening Test That Provides Expanded HPV Typing.
Demarco M; Carter-Pokras O; Hyun N; Castle PE; He X; Dallal CM; Chen J; Gage JC; Befano B; Fetterman B; Lorey T; Poitras N; Raine-Bennett TR; Wentzensen N; Schiffman M
J Clin Microbiol; 2018 May; 56(5):. PubMed ID: 29491018
[TBL] [Abstract][Full Text] [Related]
49. A systematic review and meta-analysis of studies evaluating the performance of point-of-care tests for human papillomavirus screening.
Kelly H; Mayaud P; Segondy M; Pant Pai N; Peeling RW
Sex Transm Infect; 2017 Dec; 93(S4):S36-S45. PubMed ID: 29223961
[TBL] [Abstract][Full Text] [Related]
50. Prospective comparison of hybrid capture 2 and SPF₁₀-LiPA for carcinogenic human papillomavirus detection and risk prediction of cervical cancer: a population-based cohort study in China.
Dong L; Feng RM; Zhang L; Xu XQ; Zhao XL; Wang MZ; Qiao YL; Zhao FH
J Gynecol Oncol; 2017 Sep; 28(5):e66. PubMed ID: 28657227
[TBL] [Abstract][Full Text] [Related]
51. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
Arbyn M; Snijders PJ; Meijer CJ; Berkhof J; Cuschieri K; Kocjan BJ; Poljak M
Clin Microbiol Infect; 2015 Sep; 21(9):817-26. PubMed ID: 25936581
[TBL] [Abstract][Full Text] [Related]
52. Prior cervical cytology and high-risk HPV testing results for 311 patients with invasive cervical adenocarcinoma: a multicenter retrospective study from China's largest independent operator of pathology laboratories.
Xie F; Zhang L; Zhao D; Wu X; Wei M; Zhang X; Wu X; Fang H; Xu X; Yang M; Qi D
BMC Infect Dis; 2019 Nov; 19(1):962. PubMed ID: 31711435
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the PANArray HPV Genotyping Chip Test with the Cobas 4800 HPV and Hybrid Capture 2 Tests for Detection of HPV in ASCUS Women.
Ki EY; Lee YK; Lee A; Park JS
Yonsei Med J; 2018 Jul; 59(5):662-668. PubMed ID: 29869464
[TBL] [Abstract][Full Text] [Related]
54. Comparison of Seegene Anyplex II HPV28 assay with BD Onclarity HPV assay for human papillomavirus genotyping.
Kim M; Kim J; Park NJ; Park JY
PLoS One; 2022; 17(7):e0267836. PubMed ID: 35802570
[TBL] [Abstract][Full Text] [Related]
55. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
Poljak M; Oštrbenk A
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
[TBL] [Abstract][Full Text] [Related]
56. Comparison of analytical and clinical performance of CLART HPV2 genotyping assay to Linear Array and Hybrid Capture 2: a split-sample study.
Ejegod DM; Rebolj M; Bonde J
BMC Cancer; 2015 Apr; 15():216. PubMed ID: 25886410
[TBL] [Abstract][Full Text] [Related]
57. A direct comparison of four high-risk human papillomavirus tests versus the cobas test: Detecting CIN2+ in low-resource settings.
Xue P; Gao LL; Yin J; Han LL; Zhao J; Li L; Seery S; Han XY; Li TY; Jiang Y; Chen W; Shen J
J Med Virol; 2019 Jul; 91(7):1342-1350. PubMed ID: 30854653
[TBL] [Abstract][Full Text] [Related]
58. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
[TBL] [Abstract][Full Text] [Related]
59. Cross-reactivity profiles of hybrid capture II, cobas, and APTIMA human papillomavirus assays: split-sample study.
Preisler S; Rebolj M; Ejegod DM; Lynge E; Rygaard C; Bonde J
BMC Cancer; 2016 Jul; 16():510. PubMed ID: 27439470
[TBL] [Abstract][Full Text] [Related]
60. Clinical Validation of the cobas HPV Test on the cobas 6800 System for the Purpose of Cervical Screening.
Saville M; Sultana F; Malloy MJ; Velentzis LS; Caruana M; Ip ELO; Keung MHT; Canfell K; Brotherton JML; Hawkes D
J Clin Microbiol; 2019 Feb; 57(2):. PubMed ID: 30463896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
